MetaCap

Dianthus Therapeutics Inc. (DNTH)

NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD

84.55-0.28 (-0.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DNTH stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.08
52-week range
35.84 – 117.88
Day range
82.58 – 85.67
Volume / Avg
784.84K / 848.96K
Beta
—

52-week range

$35.84$117.88

DNTH stock today

Shares of Dianthus Therapeutics (DNTH) finished lower on Nov 20 at $84.55, a drop of 0.33% or $0.28 per share, versus the S&P 500's 3.70% decline. At this level, DNTH sits in the middle of its 52-week range of $35.84 to $117.88: 28.3% below the high, set on Aug 19, 2026 and 135.9% above the low. DNTH is up 105.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 104.0%.

Dianthus Therapeutics has posted a net loss over the last twelve months (EPS of -$4.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Dianthus Therapeutics

Company profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Marino Garcia M.B.A.
Headquarters
New York, NY
Employees
92
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Dianthus Therapeutics generated $2.0 million in revenue, down 67.3% from fiscal 2024, the first decline in the 10 years shown. Dianthus Therapeutics reported a net loss of $162.3 million, compared with a loss of $85.0 million a year earlier. Operating margin was -8739.3%.

Dianthus Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.04M$6.24M$2.83M——
Growth-67.35%+120.63%———
Net income$-162.34M$-84.97M$-43.55M$-28.48M$-71.14M
EPS (diluted)$-4.20$-2.55$-8.45$-32.57$-1.29

Analyst forecast

Forecast

Consensus (18 analysts)

strong_buy

Avg. price target

$139.25+64.70%

  • Strong buy 1
  • Buy 17
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $113.00High $200.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.81 vs $1.00
Surprise
-181.00%

DNTH news

All DNTH news

Dianthus Therapeutics peers

Health Care sector
DNTH peer companies
CompanyPrice% ChgMarket capCompare
ERASErasca Inc.13.61-4.29%$4.78Bvs DNTH
PTCTPTC Therapeutics Inc.56.42-3.27%$4.71Bvs DNTH
LQDALiquidia Corporation54.43-3.88%$4.90Bvs DNTH
COGTCogent Biosciences Inc.26.72-3.69%$4.65Bvs DNTH
TVTXTravere Therapeutics Inc.47.00-2.69%$4.51Bvs DNTH
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs DNTH
IONSIonis Pharmaceuticals Inc.26.58-2.35%$4.43Bvs DNTH
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs DNTH

Indexes, lists and sector

Dianthus Therapeutics stock FAQ

What is Dianthus Therapeutics's stock price today?

DNTH last traded at $84.55 as of Nov 20, 4:00 PM EST, down 0.33% on the day. Prices are delayed at least 15 minutes.

Who is Dianthus Therapeutics's CEO?

Mr. Marino Garcia M.B.A. is the chief executive officer of Dianthus Therapeutics Inc., which has about 92 employees.

What is the DNTH 52-week high?

The 52-week high for DNTH is $117.88 and the 52-week low is $35.84. The stock is currently 28.3% below its high.

Compare DNTH